Company intelligence / Profile preview

TESARO, Inc.

Waltham, Massachusetts, United Statesorpha.net ↗

Ownership: Public · TSRO
Development stage: Commercial

Overview

Tesaro's main product Zejula (niraparib) is an oral PARP inhibitor approved for maintenance treatment of ovarian cancer. Clinical trials were investigating Zejula as monotherapy and first-line treatment for ovarian cancer across all patient populations, including those with and without BRCA mutations[3][5].

Therapeutic areas: Oncology
Modalities: PARP inhibitors
Industry: Biotech

Drug pipeline

2 assets

niraparib

Commercial

Indications: Ovarian cancer, Non-small cell lung cancer, Breast cancer

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $0
Total revenue: $64.4M
Enterprise value: $166.8M

Beyond the preview

Go deeper on TESARO, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TESARO, Inc..

Explore the full profile